Weill Cornell Medicine, New York, NY, United States.
Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Curr Top Dev Biol. 2024;156:297-331. doi: 10.1016/bs.ctdb.2024.01.009. Epub 2024 Feb 15.
Congenital heart disease (CHD) is the most common severe birth anomaly, affecting almost 1% of infants. Most CHD is genetic, but only 40% of patients have an identifiable genetic risk factor for CHD. Chromosomal variation contributes significantly to CHD but is not readily amenable to biological follow-up due to the number of affected genes and lack of evolutionary synteny. The first CHD genes were implicated in extended families with syndromic CHD based on the segregation of risk alleles in affected family members. These have been complemented by more CHD gene discoveries in large-scale cohort studies. However, fewer than half of the 440 estimated human CHD risk genes have been identified, and the molecular mechanisms underlying CHD genetics remains incompletely understood. Therefore, model organisms and cell-based models are essential tools for improving our understanding of cardiac development and CHD genetic risk. Recent advances in genome editing, cell-specific genetic manipulation of model organisms, and differentiation of human induced pluripotent stem cells have recently enabled the characterization of developmental stages. In this chapter, we will summarize the latest studies in CHD genetics and the strengths of various study methodologies. We identify opportunities for future work that will continue to further CHD knowledge and ultimately enable better diagnosis, prognosis, treatment, and prevention of CHD.
先天性心脏病(CHD)是最常见的严重出生缺陷,影响近 1%的婴儿。大多数 CHD 是遗传性的,但只有 40%的患者有可识别的 CHD 遗传风险因素。染色体变异对 CHD 有重要贡献,但由于受影响的基因数量和缺乏进化同线性,因此不易进行生物学随访。最初的 CHD 基因是根据受影响家庭成员中风险等位基因的分离,在有综合征的 CHD 的大家族中被牵连出来的。这些基因已经通过在大规模队列研究中发现更多的 CHD 基因得到了补充。然而,在估计的 440 个人类 CHD 风险基因中,不到一半已经被鉴定出来,CHD 遗传的分子机制仍不完全清楚。因此,模式生物和基于细胞的模型是提高我们对心脏发育和 CHD 遗传风险理解的重要工具。基因组编辑、模式生物的细胞特异性遗传操作以及人诱导多能干细胞的分化方面的最新进展最近使发育阶段的特征得以确定。在本章中,我们将总结 CHD 遗传学的最新研究以及各种研究方法的优势。我们确定了未来工作的机会,这些机会将继续推进 CHD 知识,并最终实现更好的 CHD 诊断、预后、治疗和预防。